Under the leadership of Professor Nick James, we are seeking to appoint a Clinical Research Fellow to join the Prostate and Bladder Cancer Research Team, to develop a research project focussing on upfront use of PSMA-Lutetium for metastatic disease which will require close collaboration with the academic and clinical physics and nuclear medicine teams at the ICR/The Royal Marsden NHS Foundation Trust (RM) and University College London (UCL). The post holder will be one of the team of follows working on various projects within the STAMPEDE trial programme, the first multi-arm, multi-stage platform trial to open (in 2004); the original trial has contributed to large-scale changes in the management of patients with advanced prostate cancer. We are now launching 3 ambitious new comparisons under the STAMPEDE2 platform. The post holder will thus be key to the set up and success of this new part of the STAMPEDE programme.
It is anticipated that the post-holder will register for an MD(Res) or a PhD at the ICR and awarded by the University of London.
A parallel position will be starting at the same time at the UCL Cancer Institute and the MRC CTU, supervised by Professor Gerhardt Attard.
Key Requirements
The post holder is expected to be a clinical or medical oncology trainee and will typically hold a national training number and plan to undertake this fellowship as out-of-program research experience ( or equivalent for other specialities). The fellowship will suit an oncology trainee who envisages a future career as a clinical researcher heavily involved in academic clinical trial development and translational research and wishes to build knowledge and skills to support this path. Medical degree and MRCP or equivalent are essential. Enrolled in or completed a training programme in oncology or a relevant speciality (UK or equivalent internationally) and relevant clinical experience treating patients with advanced prostate cancer are desirable but not essential.
Department/Directorate Information
The Division of Radiotherapy and Imaging brings together research groups that work on how to use radiation therapy, guided by state-of-the-art imaging techniques, in the most effective way to cure cancer. Our work is based on the central idea that the best outcomes will be achieved by delivering curative radiation doses to tumours, while limiting radiation damage of neighbouring normal tissues. Our therapy often includes adding drug treatments alongside radiation therapy as a means of killing cancer cells more effectively and, at the same time, activating anti-tumour immune responses. Preclinical work includes research that combines radiation therapy with radiation sensitisers and biological response modifiers (oncolytic viruses, innate immune activators, immune checkpoint inhibitors) to maximise anti-tumour efficacy and give protection against tumour recurrence. Multiple translational clinical studies seek to address these themes through our collaborators in the RM. Overall, our mission is to cure more patients with fewer immediate and long-term side effects of treatment.
We encourage all applicants to access the job pack attached for more detailed information regarding this role. For further information about the role please email Prof. Nick James ([email protected]).